RPL22 Antibody | 23-809

RPL22 Antibody | 23-809 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 1-122 of human RPL22 (NP_000974.1) .

Research Area: Other

Tested Application: WB, IHC, IF

Application: WB: 1:500 - 1:2000
IHC: 1:50 - 1:100
IF: 1:50 - 1:100

Specificiy: N/A

Positive Control 1: HeLa

Positive Control 2: U-87MG

Positive Control 3: HepG2

Positive Control 4: Jurkat

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Observed: 15kDa

Validation: N/A

Isoform: N/A

Purification: Affinity purification

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Concentration: N/A

Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.

Alternate Name: RPL22, ribosomal protein L22, EAP, HBP15, HBP15/L22, 60S ribosomal protein L22, EBER-associated protein, Epstein-Barr virus small RNA-associated protein, Epstein-Barr-encoded RNA-associated protein, heparin-binding protein 15, heparin-binding protein HBp15, L22

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a cytoplasmic ribosomal protein that is a component of the 60S subunit. The protein belongs to the L22E family of ribosomal proteins. Its initiating methionine residue is post-translationally removed. The protein can bind specifically to Epstein-Barr virus-encoded RNAs (EBERs) 1 and 2. The mouse protein has been shown to be capable of binding to heparin. Transcript variants utilizing alternative polyA signals exist. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. It was previously thought that this gene mapped to 3q26 and that it was fused to the acute myeloid leukemia 1 (AML1) gene located at 21q22 in some therapy-related myelodysplastic syndrome patients with 3;21 translocations; however, these fusions actually involve a ribosomal protein L22 pseudogene located at 3q26, and this gene actually maps to 1p36.3-p36.2.